{"id":7797,"date":"2026-02-24T06:08:28","date_gmt":"2026-02-24T06:08:28","guid":{"rendered":"https:\/\/pandapeptides.com\/research\/tesamorelin\/"},"modified":"2026-04-09T14:26:03","modified_gmt":"2026-04-09T21:26:03","slug":"tesamorelin","status":"publish","type":"page","link":"https:\/\/pandapeptides.com\/es\/research\/tesamorelin\/","title":{"rendered":"Tesamorelin \u2014 Published Research"},"content":{"rendered":"
\n

\u2190 Back to Tesamorelin product page<\/a><\/p>\n

Ver reportes de laboratorio<\/a> \u00b7 Calidad y pruebas<\/a> \u00b7 Preguntas frecuentes<\/a><\/p>\n

\n

Biblioteca de investigaci\u00f3n<\/h3>\n

Published research on tesamorelin \u2014 for educational purposes only<\/p>\n

\nTesamorelin Structure and GHRH Receptor Agonism<\/summary>\n
\n

Tesamorelin retains the full 44-amino-acid sequence of human GHRH(1-44) with a trans-3-hexenoic acid (C6) moiety conjugated to the N-terminal tyrosine via an amide bond. This modification protects the Tyr\u00b9-Ala\u00b2 bond from DPP-IV cleavage (the primary inactivation pathway for native GHRH) while preserving binding to the GHRH receptor. Receptor binding studies show similar affinity (Kd ~0.3 nM) and maximal cAMP response compared to native GHRH. The modification extends the functional half-life without preventing renal clearance. Research compound \u2014 not for human use.<\/p>\n

Boulanger L et al. “Pharmacological and structural characterization of growth hormone-releasing factor analogs.” Peptides.<\/em> 2005. PubMed<\/a><\/p>\n<\/div>\n<\/details>\n

\nGHRH Receptor Signal Transduction<\/summary>\n
\n

The GHRH receptor (GHRHR) is a class B G protein-coupled receptor expressed predominantly on anterior pituitary somatotrophs. Ligand binding activates G\u03b1s-mediated adenylyl cyclase signaling, increasing intracellular cAMP and activating protein kinase A (PKA). PKA phosphorylation cascades regulate GH gene transcription via CREB and Pit-1 transcription factors, and trigger secretory granule exocytosis. GHRHR also signals through phospholipase C in some contexts, generating IP3 and mobilizing intracellular calcium. Research compound \u2014 not for human use.<\/p>\n

Mayo KE et al. “Growth hormone-releasing hormone: synthesis and signaling.” Recent Prog Horm Res.<\/em> 2000. PubMed<\/a><\/p>\n<\/div>\n<\/details>\n

\nGHRH Analogs and Somatotroph Proliferation<\/summary>\n
\n

In addition to stimulating acute GH release, GHRH receptor activation promotes somatotroph proliferation and differentiation through cAMP-dependent and Wnt\/\u03b2-catenin signaling pathways. Studies in GHRH-knockout mouse models demonstrate that absence of endogenous GHRH results in severe pituitary hypoplasia and dwarfism, while exogenous GHRH analog administration partially restores somatotroph populations and somatic growth. These models characterize the trophic role of GHRH signaling in pituitary development. Research compound \u2014 not for human use.<\/p>\n

Alba M, Bhangoo A, Bhatt S, Bhatt R. “The GH axis in the GHRH KO mouse.” Rev Endocr Metab Disord.<\/em> 2005. PubMed<\/a><\/p>\n<\/div>\n<\/details>\n<\/div>\n

\n

Disclaimer:<\/strong> All research citations are provided as references to published laboratory literature only. These materials may summarize in vitro and animal-model findings. Products are sold strictly for laboratory research use. No statements on this page are intended as dosing, administration, treatment, or other human-use guidance.<\/p>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"

\u2190 Back to Tesamorelin product page View Lab Reports \u00b7 Quality & Testing \u00b7 FAQ Research Library Published research on tesamorelin \u2014 for educational purposes only Tesamorelin Structure and GHRH Receptor Agonism Tesamorelin retains the full 44-amino-acid sequence of human GHRH(1-44) with a trans-3-hexenoic acid (C6) moiety conjugated to the N-terminal tyrosine via an amide […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":7787,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-7797","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7797","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/comments?post=7797"}],"version-history":[{"count":3,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7797\/revisions"}],"predecessor-version":[{"id":8628,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7797\/revisions\/8628"}],"up":[{"embeddable":true,"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/pages\/7787"}],"wp:attachment":[{"href":"https:\/\/pandapeptides.com\/es\/wp-json\/wp\/v2\/media?parent=7797"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}